AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2950015 — intervention group
Group type: EXPERIMENTAL
Intervention: misoprostol (a prostaglandin E1 analogue)
Number of subjects: 18
Study 2950015 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 31899746 — intervention group
Group type: EXPERIMENTAL
Intervention: Deceptive placebo (DP)
Number of subjects: 117
Study 31899746 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) with positive expectancies
Number of subjects: 117
Study 31899746 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) with raised hope
Number of subjects: 117
Study 31899746 — intervention group
Group type: COMPARATOR
Intervention: No treatment (NT)
Number of subjects: 117
Study 28981303 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective mental contrasting intervention
Number of subjects: 110
Study 28981303 — intervention group
Group type: COMPARATOR
Intervention: Instrumental mental contrasting intervention
Number of subjects: 110
Study 28981303 — intervention group
Group type: COMPARATOR
Intervention: Standard mental contrasting intervention
Number of subjects: 110
Study 27451347 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids and severity-specific inhaled bronchodilator therapy
Number of subjects: 973
Study 27451347 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral detection
Number of subjects: 973
Study 27451347 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever
Number of subjects: 973
Study 27451347 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PRAM score
Number of subjects: 973
Study 27451347 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen saturation < 92%
Number of subjects: 973
Study 27451347 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of symptoms between exacerbations
Number of subjects: 973
Study 27451347 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral detection in preschoolers
Number of subjects: 973
Study 27451347 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever in preschoolers
Number of subjects: 973
Study 24661661 — intervention group
Group type: COMPARATOR
Intervention: CIMRT (75.6 Gy in 1.8‐Gy fractions)
Number of subjects: 203
Study 24661661 — intervention group
Group type: EXPERIMENTAL
Intervention: HIMRT (72 Gy in 2.4‐Gy fractions)
Number of subjects: 203
Study 21971082 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized powder of enzymolyzed honeybee larvae
Number of subjects: 60
Study 21971082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20417770 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell saver group
Number of subjects: 29
Study 20417770 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 18626172 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (A + B)
Number of subjects: 13
Study 18626172 — intervention group
Group type: COMPARATOR
Intervention: Control (B)
Number of subjects: 13
Study 15923168 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for multiple myeloma
Number of subjects: 1
Study 15923168 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel filtration of serum
Number of subjects: 1
Study 15923168 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical stains
Number of subjects: 1
Study 12766964 — intervention group
Group type: EXPERIMENTAL
Intervention: MedioStar laser
Number of subjects: 29
Study 12766964 — intervention group
Group type: COMPARATOR
Intervention: LightSheer laser
Number of subjects: 29
Study 10348279 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation and Misonidazole
Number of subjects: 120
Study 10348279 — intervention group
Group type: COMPARATOR
Intervention: Irradiation alone
Number of subjects: 120
Study 8522640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 41-3696 at doses of 10 mg and 30 mg
Number of subjects: 36
Study 8522640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 41-3696
Number of subjects: 36
Study 8522640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 41-3696 and Ro 41-3290
Number of subjects: 36
Study 1682684 — intervention group
Group type: EXPERIMENTAL
Intervention: B-subunit/whole-cell cholera vaccine (BS-WC)
Number of subjects: 615
Study 1682684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 615
Study 6963076 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PGE2
Number of subjects: 0
Study 6963076 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous PGE2
Number of subjects: 0
Study 6963076 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 tablets intravaginally
Number of subjects: 0
Study 6963076 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 0
Study 31320694 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater quantity and variety of snack items
Number of subjects: 1299
Study 31320694 — intervention group
Group type: COMPARATOR
Intervention: Box size manipulation
Number of subjects: 1299
Study 31320694 — intervention group
Group type: COMPARATOR
Intervention: Quantity/variety of items
Number of subjects: 1299
Study 27936376 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Network Counseling (PNC)
Number of subjects: 46
Study 27936376 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 46
Study 27751553 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (diaphragm pacing)
Number of subjects: 74
Study 27751553 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control)
Number of subjects: 74
Study 24359932 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 0
Study 24359932 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 0
Study 22866289 — intervention group
Group type: EXPERIMENTAL
Intervention: NAI (variable‐thread design, NobelActive internal connection)
Number of subjects: 177
Study 22866289 — intervention group
Group type: EXPERIMENTAL
Intervention: NAE (variable‐thread design, NobelActive external connection)
Number of subjects: 177
Study 22866289 — intervention group
Group type: COMPARATOR
Intervention: NR (standard tapered design, NobelReplace tapered groovy)
Number of subjects: 177
Study 18403375 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 312
Study 18403375 — intervention group
Group type: EXPERIMENTAL
Intervention: Working
Number of subjects: 312
Study 17522399 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced life support (ALS) treatment, including endotracheal intubation and intravenous drugs, administered to 56.6% of patients during the second phase.
Number of subjects: 8138
Study 17522399 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation performed in 1.4% of patients during the second phase.
Number of subjects: 8138
Study 17522399 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous drugs administered to 15.0% of patients during the second phase.
Number of subjects: 8138
Study 17522399 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of nebulized salbutamol and sublingual nitroglycerin increased during the second phase.
Number of subjects: 8138
Study 14742379 — intervention group
Group type: EXPERIMENTAL
Intervention: memantine (30 mg/d)
Number of subjects: 8
Study 14742379 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study 11167376 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with polyurethane-coated cotton encasings for bedding
Number of subjects: 40
Study 11167376 — intervention group
Group type: COMPARATOR
Intervention: Placebo with cotton covers
Number of subjects: 40
Study 9459625 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine treatment (interferon-alpha or interferon-beta, either alone or in combination with interleukin-2 or antineoplastic agents)
Number of subjects: 166
Study 9459625 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients suffering from ATD)
Number of subjects: 166
Study 7949265 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA (10 mg/kg/day for 15-20 days)
Number of subjects: 28
Study 7949265 — intervention group
Group type: EXPERIMENTAL
Intervention: CDCA (15 mg/kg/day for 15-20 days)
Number of subjects: 28
Study 7949265 — intervention group
Group type: COMPARATOR
Intervention: Untreated subjects (control)
Number of subjects: 28
Study 7949265 — intervention group
Group type: EXPERIMENTAL
Intervention: CDCA treated group
Number of subjects: 28
Study 7949265 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA treated group
Number of subjects: 28
Study 2851180 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (120 mg/m2 on day 1)
Number of subjects: 156
Study 2851180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (120 mg/m2 on day 1) plus etoposide (VP‐16) (100 mg/m2 on days 1‐3)
Number of subjects: 156
Study 2851180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (120 mg/m2 on day 1) plus etoposide (VP‐16) (100 mg/m2 on days 1‐3) plus mitomycin C (10 mg/m2 on days 1, 21, and 42; then every 6 weeks for a maximum dose of 100 mg)
Number of subjects: 156
Study 2851180 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (cisplatin and etoposide)
Number of subjects: 156
Study 2851180 — intervention group
Group type: COMPARATOR
Intervention: Single agent (cisplatin)
Number of subjects: 156
Study 31373868 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIRIT in person (in a private room in a memory clinic)
Number of subjects: 23
Study 31373868 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIRIT remote (via videoconferencing from home)
Number of subjects: 23
Study 31373868 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIRIT (both in person and remote)
Number of subjects: 23
Study 28591061 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic resistance exercise training (RET) for 12 weeks
Number of subjects: 46
Study 28591061 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RET intervention)
Number of subjects: 46
Study 25539672 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection (EMR) followed by radiofrequency ablation (RFA)
Number of subjects: 508
Study 23908490 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational tuberculosis vaccine
Number of subjects: 0
Study 23908490 — intervention group
Group type: COMPARATOR
Intervention: BCG-immunized HIV-infected adults
Number of subjects: 0
Study 21378711 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamberin in a dose of 400-800 ml
Number of subjects: 0
Study 21378711 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 19077155 — intervention group
Group type: EXPERIMENTAL
Intervention: Purely cancellous bone (PCB)
Number of subjects: 15
Study 19077155 — intervention group
Group type: COMPARATOR
Intervention: Corticocancellous iliac bone grafts (50% cancellous and 50% cortical)
Number of subjects: 15
Study 17287313 — intervention group
Group type: EXPERIMENTAL
Intervention: MenC‐TT plus DTPa‐HBV‐IPV/Hib
Number of subjects: 520
Study 17287313 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib‐MenC‐TT plus DTPa‐HBV‐IPV
Number of subjects: 520
Study 17287313 — intervention group
Group type: COMPARATOR
Intervention: MenC‐CRM(197) plus DTPa‐HBV‐IPV/Hib
Number of subjects: 520
Study 17287313 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster doses
Number of subjects: 520
Study 15534017 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual support intervention (N=32)
Number of subjects: 96
Study 15534017 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation intervention (N=33)
Number of subjects: 96
Study 15534017 — intervention group
Group type: COMPARATOR
Intervention: Standard care (N=31)
Number of subjects: 96
Study 12151142 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular diet as the first postoperative meal
Number of subjects: 254
Study 12151142 — intervention group
Group type: COMPARATOR
Intervention: Clear liquid diet as the first postoperative meal
Number of subjects: 254
Study 9880125 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 1917
Study 7911677 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and postoperative chemotherapy (5-drug-combination + tamoxifen)
Number of subjects: 105
Study 7911677 — intervention group
Group type: COMPARATOR
Intervention: Pre- and postoperative radiotherapy
Number of subjects: 105
Study 2680432 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 230
Study 2680432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 1244627 — intervention group
Group type: EXPERIMENTAL
Intervention: Mismatch tones (5%, 25%, or 100% different in pitch)
Number of subjects: 0
Study 1244627 — intervention group
Group type: COMPARATOR
Intervention: Reading a book (control condition)
Number of subjects: 0
Study 1244627 — intervention group
Group type: EXPERIMENTAL
Intervention: Responding with a button press (active condition)
Number of subjects: 0
Study 31752624 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual metaphor with death-based fear appeal
Number of subjects: 0
Study 31752624 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual metaphor with appearance-based fear appeal
Number of subjects: 0
Study 31752624 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal metaphor with death-based fear appeal
Number of subjects: 0
Study 31752624 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal metaphor with appearance-based fear appeal
Number of subjects: 0
Study 31752624 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for cognition
Number of subjects: 0
Study 31752624 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived message effectiveness
Number of subjects: 0
Study 31373827 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing meditation program (8 weeks)
Number of subjects: 55
Study 31373827 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment + observation)
Number of subjects: 55
Study 27492888 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-visit program (multidisciplinary team visit, fall risk assessment with feedback, fall prevention lecture)
Number of subjects: 603
Study 27492888 — intervention group
Group type: COMPARATOR
Intervention: Year-round comprehensive program (visits every 3 months)
Number of subjects: 603
Study 27492888 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified version of the single-visit program
Number of subjects: 603
Study 26271869 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% CHX‐alcohol
Number of subjects: 319
Study 26271869 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% CHX‐alcohol‐free
Number of subjects: 319
Study 26271869 — intervention group
Group type: COMPARATOR
Intervention: Brushing alone
Number of subjects: 319
Study 21925749 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cardiovascular risk factors (obesity, blood pressure, lipids, smoking habits)
Number of subjects: 441
Study 21925749 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel cardiovascular risk factors (PAI-1, platelet count, total homocysteine, C-reactive protein)
Number of subjects: 441
Study 21925749 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of vascular damage (carotid IMT, vWF, e‐selectin)
Number of subjects: 441
Study 21925749 — intervention group
Group type: COMPARATOR
Intervention: Age, obesity, and conventional risk factors
Number of subjects: 441
Study 21925749 — intervention group
Group type: COMPARATOR
Intervention: Novel cardiovascular risk factors
Number of subjects: 441
Study 22673924 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg daily)
Number of subjects: 67
Study 22673924 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 U daily)
Number of subjects: 67
Study 22673924 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice (control)
Number of subjects: 67
Study 19481022 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI (pantoprazole 40 mg/day)
Number of subjects: 33
Study 17372321 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-absorptive exercise (at approximately 60% of VO2max for 45 minutes)
Number of subjects: 7
Study 17372321 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial exercise (at approximately 60% of VO2max for 45 minutes)
Number of subjects: 7
Study 17372321 — intervention group
Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 7
Study 17372321 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-absorptive exercise
Number of subjects: 7
Study 17372321 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial exercise
Number of subjects: 7
Study 15206014 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of a second opioid at low doses (initial equivalent dosage of 20% of previous therapy)
Number of subjects: 14
Study 15206014 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of a second opioid at low doses
Number of subjects: 14
Study 11444416 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium (400 microg/d as Cr pidolate)
Number of subjects: 0
Study 11444416 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (30 mg/d as Zn gluconate)
Number of subjects: 0
Study 11444416 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Zinc and Chromium supplementation
Number of subjects: 0
Study 11444416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10093319 — intervention group
Group type: EXPERIMENTAL
Intervention: New transit work regimens at Nadymgazprom Enterprise
Number of subjects: 240
Study 10093319 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological status assessment using the method of Taylor
Number of subjects: 240
Study 10093319 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological rhythms, chemical control of ventilation, O2 and CO2 consumption, body temperature, hormone‐metabolic data
Number of subjects: 240
Study 10093319 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory processes
Number of subjects: 240
Study 8058229 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2 g/day of oral elemental calcium)
Number of subjects: 281
Study 8058229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 2512104 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital administered by primary health care workers trained by a three-day course in community 'A'
Number of subjects: 40
Study 2512104 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital administered by neurologists in community 'B'
Number of subjects: 40
Study 1113762 — intervention group
Group type: EXPERIMENTAL
Intervention: 125I fibrinogen count scanning
Number of subjects: 83
Study 1113762 — intervention group
Group type: COMPARATOR
Intervention: Phlebography
Number of subjects: 83
Study 31794952 — intervention group
Group type: EXPERIMENTAL
Intervention: VSI Patient Education (VSI PE) using HoloLens® glasses
Number of subjects: 17
Study 31794952 — intervention group
Group type: COMPARATOR
Intervention: Rubber brain model (3B Scientific®)
Number of subjects: 17
Study 31204254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lumbar plexus and sciatic nerve blocks with ropivacaine (regional anesthesia)
Number of subjects: 20
Study 31204254 — intervention group
Group type: COMPARATOR
Intervention: Sham blocks with saline (control)
Number of subjects: 20
Study 31204254 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 20
Study 31204254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lumbar plexus and sciatic nerve blocks with electrostimulation
Number of subjects: 20
Study 28685353 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon beta-1a 125 mcg
Number of subjects: 1512
Study 25381447 — intervention group
Group type: EXPERIMENTAL
Intervention: Monolingual treatment
Number of subjects: 29
Study 25381447 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilingual treatment
Number of subjects: 29
Study 25381447 — intervention group
Group type: COMPARATOR
Intervention: No-treatment (delayed-treatment)
Number of subjects: 29
Study 22922803 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load resistance training (LLRT) with blood flow restriction (BFR)
Number of subjects: 7
Study 22922803 — intervention group
Group type: COMPARATOR
Intervention: Low-load resistance training (LLRT) without blood flow restriction (BFR)
Number of subjects: 7
Study 21258893 — intervention group
Group type: EXPERIMENTAL
Intervention: Proscar combined with Aike Mixture (AKM)
Number of subjects: 60
Study 21258893 — intervention group
Group type: COMPARATOR
Intervention: Proscar only (Control)
Number of subjects: 60
Study 19092669 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting Heart system
Number of subjects: 93
Study 19092669 — intervention group
Group type: EXPERIMENTAL
Intervention: MECC system
Number of subjects: 93
Study 19092669 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECiSe system
Number of subjects: 93
Study 19092669 — intervention group
Group type: COMPARATOR
Intervention: cECC (HL30 Maquet)
Number of subjects: 93
Study 19092669 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 93
Study 16777684 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with advanced NSCLC
Number of subjects: 50
Study 16777684 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 50
Study 16019861 — intervention group
Group type: EXPERIMENTAL
Intervention: Local hyperthermia treatment (Group A)
Number of subjects: 40
Study 16019861 — intervention group
Group type: COMPARATOR
Intervention: Post-operative follow-up (Group B)
Number of subjects: 40
Study 12496532 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic palliation
Number of subjects: 297
Study 12496532 — intervention group
Group type: COMPARATOR
Intervention: Surgical palliation
Number of subjects: 297
Study 12496532 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic staging
Number of subjects: 297
Study 12496532 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 297
Study 10522998 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg triptorelin im every 4 weeks for 2 years (n = 20)
Number of subjects: 30
Study 10522998 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n = 10)
Number of subjects: 30
Study 7730651 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 (1, 10, or 25 micrograms/kg)
Number of subjects: 17
Study 1696418 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparatory information with video film (n = 26)
Number of subjects: 60